SenseTime Spins Off New AI Healthcare Company, Raises USD 141 Million in Six Months, Aiming to Build a “Medical World Model”
Want to read in a language you're more familiar with?
SenseTime’s newly spun-off AI healthcare company has raised USD 141 million in six months and unveiled its vision to build a “medical world model,” deploying advanced AI solutions across hospitals, research, and international markets.
On December 2, 2025, the executive team of SenseTime’s newly spun-off AI healthcare company made its first public appearance, outlining its ambition to serve as both the **designer and enabler of “future hospitals” **and to develop a medical world model. The company has raised a total of USD 141 Million within just six months, backed by investors including the Midea-affiliated Yingfeng Holding, People’s Medical Publishing House Technology, and Lenovo Capital. Its Series A funding round has officially begun. As a core extension of **SenseTime’s “1+X” **strategic ecosystem, the new venture receives comprehensive technical and strategic support from the group.
From a technical standpoint, the company follows a “general-purpose + specialized” hybrid architecture, with its self-developed medical large language model **DaYi® (“Great Doctor”) **as the central engine, coordinating a cluster of multimodal foundation models and a medical knowledge base. DaYi® reportedly ranks first across eight dimensions of professional evaluation, powered by a high-quality medical corpus of more than 400 billion Chinese characters, an industrial-grade RAG framework, and dedicated clinical-reasoning training—significantly reducing hallucinations and improving decision accuracy in complex scenarios. To streamline development, the company has built dual middle-office platforms to support AI agent creation and medical imaging AI production, from which three standardized products have already been incubated.
Leveraging its core technologies, the company has launched the SenseCare® Smart Hospital integrated solution, covering clinical care, patient services, scientific research, and cloud platform capabilities. On the clinical side, more than 40 AI modules are now available. Its pathology-AI diagnostic system can improve efficiency by 30%–50%, while a liver-surgery intelligent decision system—co-developed with Tsinghua Chang Gung Hospital—supports the entire surgical workflow. On the patient side, the platform offers comprehensive appointment, treatment, and mobile health-management services. For researchers, the DaYi Research Assistant provides end-to-end support, including paper drafting and literature analysis.
Commercial deployment has produced strong results. Together with Ruijin Hospital, the company developed the “Ruijin Medical Digital Human,” which has assisted in over 400 complex liver resections. Its research platform built with Roche Pharmaceuticals now covers 700 top-tier hospitals, saving more than 20,000 hours in research time. The company is also working with Shanghai Shenkang to build China’s largest medical big-data training facility. Its products have entered Lenovo’s omni-channel ecosystem, and its smart-diagnosis platform has been deployed across medical institutions under Midea Group. Overseas expansion is accelerating as well: it has obtained Singapore’s first AI medical-device certification with hospital deployment underway, and secured its first project in Indonesia.
Looking ahead, the company plans to focus on building a comprehensive medical world model, enabling AI to evolve from merely answering questions to simulating outcomes and assisting in decision-making. SenseTime, meanwhile, continues to advance its broader “1+X” strategy and has made new breakthroughs in spatial intelligence. Key personnel from the group will lead discussions on medical imaging and other frontier topics at CVPR 2026.
